Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andreas Hünnemeyer
Observed names:
A Hünnemeyer,
A. Hünnemeyer
Institution:
Boehringer Ingelheim (Germany)
Observed institution:
Boehringer Ingelheim (Germany)
OpenAlex ID:
A5065980128
Investigation of a Potential Food Effect on the Pharmacokinetics of Roflumilast, an Oral, Once‐Daily Phosphodiesterase 4 Inhibitor, in Healthy Subjects
2006
·
Bernhard Hauns
, Robert Hermann
, et al.
·
The Journal of Clinical Pharmacology
·
43
Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model
2010
·
Gezim Lahu
, Andreas Hünnemeyer
, et al.
·
Clinical Pharmacokinetics
·
34
PDF
Pharmacokinetic evaluation of roflumilast
2011
·
Gezim Lahu
, Nassr Nassr
, et al.
·
Expert Opinion on Drug Metabolism & Toxicology
·
22
The Targeted Oral, Once‐Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions
2009
·
Gabriele M. Böhmer
, Nassr Nassr
, et al.
·
The Journal of Clinical Pharmacology
·
17
Magnesium Hydroxide/Aluminium Hydroxide‐Containing Antacid Does Not Affect the Pharmacokinetics of the Targeted Phosphodiesterase 4 Inhibitor Roflumilast
2007
·
Nassr Nassr
, Gezim Lahu
, et al.
·
The Journal of Clinical Pharmacology
·
17
Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study
2011
·
T.D. Bethke
, M. Hartmann
, et al.
·
International Journal of Clinical Pharmacology and Therapeutics
·
15
Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults
2011
·
G. Böhmer
, C.H. Gleiter
, et al.
·
International Journal of Clinical Pharmacology and Therapeutics
·
10
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
2020
·
Tobias Litzenburger
, Jürgen Steffgen
, et al.
·
British Journal of Clinical Pharmacology
·
5
PDF
Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials
2026
·
Andreas Hünnemeyer
, Yoichiro Ogama
, et al.
·
Journal of Psychopharmacology
·
1
PDF
32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers
2019
·
Tobias Litzenburger
, Fabian Müller
, et al.
·
Lupus Science & Medicine
·
1
PDF
An Evaluation of the Effects of Roflumilast on Cardiac Repolarization, Pharmacokinetics, Safety, and Tolerability in Healthy Volunteers
2012
·
Andreas Hünnemeyer
Wirkung von weiblichen Hormonen (steady-state) auf die Pharmakokinetik von Roflumilast und Roflumilast-N-Oxid bei einer Einmalgabe
2012
·
N Nassr
, A Hünnemeyer
, et al.
·
Pneumologie
Effects of steady-state female hormones on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide
2011
·
Nassr Nassr
, Andreas Hünnemeyer
, et al.
·
European Respiratory Journal
Pharmakokinetik des oralen PDE4 Hemmers Roflumilast bei gleichzeitiger Gabe von antimikrobiellen Substanzen bei gesunden Probanden
2011
·
T Bethke
, A Hünnemeyer
, et al.
·
Pneumologie
Untersuchungen zur kardiovaskulären Sicherheit von Roflumilast
2010
·
T Bethke
, A Hünnemeyer
, et al.
·
Pneumologie
Pharmakokinetik des selektiven Phosphodiesterease 4 (PDE4)-Inhibitors Roflumilast
2010
·
T Bethke
, B Hauns
, et al.
·
Pneumologie
Pharmakokinetik von Roflumilast bei gleichzeitiger oraler Gabe von Inhibitoren und Induktoren des Cytochrom (CYP) P450 Systems
2010
·
G Lahu
, A Hünnemeyer
, et al.
·
Pneumologie
Show more works
View as search
Works count:
17
Citation count:
165
H-index:
7
I10-index:
7
Year
Topic
Type
